17.00: Introduction of the sessions
           - Prof. Martine Piccart - Institut Jules Bordet & ULB, Oncology
           - Mr. Nicola Bencini - Novartis Oncology General Manager

Part 1: International advances in technology & research: on their
           way to Belux?
           Moderated by Prof. Patrick Neven
           University Hospitals Leuven, Gynaecology

17.10: Artificial Intelligence within pathology: how is it enhancing 
           Breast Cancer diagnosis today?
           Dr. Glenn Broeckx
           Universitair Ziekenhuis Antwerpen, Pathology

17.30: How can transcriptomic analysis guide early systemic 
           treatment in TNBC?
           Prof. Christos Sotiriou
           Institut Jules Bordet & ULB, Oncology

17.50: De-escalation of systemic therapy in Breast Cancer:
           when and how?
           Prof. Martine Piccart
           Institut Jules Bordet & ULB, Oncology

18.10: Panel discussion with speakers on the clinical implications
           for the BeLux
           - Prof. François Duhoux - UCL St-Luc, Oncology
           - Dr. Caroline Duhem - CH de Luxembourg, Oncology

18.40 Break

Part 2: Recent therapeutic evolutions in advanced Breast Cancer.
            Moderated by Prof. Ahmad Awada 
            Institut Jules Bordet & ULB, Oncology

18.50: 1 year of scientific progress in advanced Breast Cancer:
           practice-changing news?
           Dr Kevin Punie
           University Hospitals Leuven, Oncology

19.10: The Belgian reimbursement system in a nutshell: Breast 
           Cancer-illustrated
           Dr. Kristel De Gauquier
           Medical Director, Pharma.be

19.30: Debate on the future of access to innovation in Belgium:
           what can we expect?
           - Dr. Diane Kleinermans - President of the Commission of Drug 
           Reimbursement RIZIV/INAMI
           - Dr. Kristel De Gauquier - Medical Director, Pharma.be
           - Prof. Martine Piccart - Institut Jules Bordet & ULB,
           Oncology
           - Panel member 4 being confirmed
         
20.10: Closing of the sessions
           Mr. Nicola Bencini
           Novartis Oncology General Manager
​​​​​​​